Healthcare Economics & Policy

Cardiologist John Stobeck, accused of inappropriately touching a female patient during a medical exam in 2012, headed to trial on Tuesday, the North Jersey Record reports.

Torrent Pharmaceuticals Limited is the latest drug company to issue a recall of losartan potassium, a popular blood pressure drug that’s been under scrutiny for more than a year for containing probable human carcinogens.

North Carolina Children’s Hospital has received the go-ahead from an external advisory board to resume complex heart surgeries after a New York Times investigation ground the program to a halt three months ago, the Times reports.

The American College of Cardiology on Sept. 16 issued its first-ever health policy statement on cardiologist compensation and opportunity equity, marking the first in a series of ACC workforce documents that will reportedly address workplace equality.

The American Society of Nuclear Cardiology, together with eight other nuclear medicine and cardiology societies, have published a consensus document outlining the best practices for imaging and diagnosing cardiac amyloidosis.

The FDA announced Sept. 13 it identified low levels of N-nitrosodimethylamine, or NDMA, in popular heartburn drugs including Zantac.

The FDA issued a warning letter to e-cigarette giant Juul early this week accusing the company of illegally promoting its vaping products as safer than cigarettes.

Investigators from the New York State Department of Health believe they’ve identified the culprit behind the recent onslaught of vaping-related illnesses in the U.S., Health Exec reports.

French medtech startup Robocath has raised 5 million euros—the equivalent of $5.5 million in U.S. currency—in support of its cardiovascular robotics system, the company announced this month.

Researchers have uncovered evidence of a global “epidemiological transition” that’s seeing cancer overtake cardiovascular disease as the biggest killer in developed countries, Reuters reports.

The U.S. FDA this month granted Fast Track designation to AstraZeneca for the development of Farxiga, or dapagliflozin. 

Cardiology compensation jumped 4.4% while productivity remained relatively stagnant between 2017 and 2018, AMGA reported in its 32nd annual Medical Group Compensation and Productivity Survey.